BioSpace News Archive

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

First Wave BioPharma, Inc., today announced that James Sapirstein, Chairman, President and CEO First Wave BioPharma, has issued a Letter to Stockholders to provide an update on the Company’s clinical programs and recent events.

September 19, 2022
·
7 min read
Deals

H-CYTE Announces Intent to Acquire SkinDisc, Expects to Complete Within 30 DaysWound Healing and Limb Salvaging Technology Adds to Company’s Asset Portfolio Focused on Unmet Medical Needs

H-CYTE, Inc. announced today that the Company has entered into a letter of intent to acquire SkinDisc, a patent pending tissue regeneration technology, that is expected to close within the next 30 days.

September 19, 2022
·
2 min read
Biotech Beach

Codex DNA Debuts Next-Generation Automated Synthetic Biology WorkstationBioXp™ 9600 system

Codex DNA, Inc. today announced commercial release and first shipment of the BioXp™ 9600 system, a next-generation high throughput platform designed to revolutionize synthetic biology workflows.

September 19, 2022
·
3 min read
MIMEDX Announces Launch of AMNIOEFFECT™

MiMedx Group, Inc. today announced the launch of AMNIOEFFECT™, a tri-layer PURION® processed human tissue allograft consisting of the amnion, intermediate, and chorion membrane layers of the placenta.

September 19, 2022
·
3 min read
Business

Microbot Medical Attracts Another Leading Physician and Expands Capabilities of its Scientific Advisory Board with Addition of Dr. Ripal Gandhi

Microbot Medical Inc. (Nasdaq: MBOT), continuing its recent success of strengthening its Scientific Advisory Board with the recent recruitment of Key Opinion Leaders (KOLs), today announced that Ripal T. Gandhi, MD, FSVM, will join the Company’s robust Scientific Advisory Board (SAB).

September 19, 2022
·
4 min read
Deals

Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock

Allakos Inc. today announced the pricing of an underwritten offering of 29,882,000 shares of its common stock at an offering price of $5.02 per share.

September 19, 2022
·
3 min read
Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has decided to advance its investigation of NP-120 (Ifenprodil) for IPF with cough as its key indication.

September 19, 2022
·
4 min read
Drug Development

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

Psyence Group Inc. is delighted to announce that it has received approval for its Phase IIa clinical trial from the Medicines and Healthcare products Regulatory Agency (MHRA), the UK equivalent regulatory body to Canada’s Health Canada and the US’s FDA.

September 19, 2022
·
5 min read
Drug Development

XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration

XORTX Therapeutics Inc. is pleased to announce completion of the previously announced Type B Pre-phase 3 meeting with the US Food and Drug Administration (“FDA”) held on September 16, 2022.

September 19, 2022
·
7 min read
Drug Development

PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery

PolyPid Ltd. today announced the peer-reviewed publication of positive clinical data from the previously completed Phase 2 study of D-PLEX 100 for the prevention of surgical site infections (SSIs) in abdominal surgery.

September 19, 2022
·
6 min read